Louis J. Arcudi
President at Millendo Therapeutics US, Inc.
Louis J. Arcudi active positions
Companies | Position | Start | End |
---|---|---|---|
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | President | - | - |
Treasurer | - | - |
Career history of Louis J. Arcudi
Former positions of Louis J. Arcudi
Companies | Position | Start | End |
---|---|---|---|
MILLENDO THERAPEUTICS | Director/Board Member | 2021-01-31 | 2021-06-24 |
Chief Executive Officer | 2021-01-31 | 2021-06-24 | |
Director of Finance/CFO | 2018-10-31 | 2021-01-31 | |
President | 2021-01-31 | 2021-06-24 | |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Comptroller/Controller/Auditor | 2007-11-30 | 2018-10-30 |
Chief Operating Officer | 2007-11-30 | 2018-10-30 | |
Director of Finance/CFO | 2007-11-30 | 2018-10-30 | |
Investor Relations Contact | 2007-11-30 | 2014-12-01 | |
Corporate Secretary | 2007-11-30 | - | |
Treasurer | 2007-11-30 | 2018-10-30 | |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Chief Administrative Officer | 2002-05-31 | 2007-11-30 |
Director of Finance/CFO | 2002-05-31 | 2007-11-30 | |
Treasurer | 2002-05-31 | 2007-11-30 | |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a private company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Chief Administrative Officer | 1999-12-31 | 2002-12-31 |
Director of Finance/CFO | 1999-12-31 | 2002-12-31 | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2002-12-31 | 2002-12-31 |
Director of Finance/CFO | 2002-12-31 | 2002-12-31 | |
COGNEX CORPORATION | Comptroller/Controller/Auditor | - | - |
Training of Louis J. Arcudi
Southern New Hampshire University | Undergraduate Degree |
Bryant University | Masters Business Admin |
Statistics
International
United States | 10 |
Operational
Director of Finance/CFO | 5 |
Treasurer | 3 |
Comptroller/Controller/Auditor | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Electronic Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
COGNEX CORPORATION | Electronic Technology |
Private companies | 6 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a private company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Health Technology |
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
- Stock Market
- Insiders
- Louis J. Arcudi
- Experience